Use of Novel Imaging for Patient Selection for Stereotactic Ablative Radiotherapy (SABR) in Oligometastatic Prostate Cancer (PCa): Does the PET Tracer Make a Difference?

J.R Galante,S Adeleke,M Wong,A Choy,K Lees,A Edwards,R Raman,C Thomas,H Taylor,J Pang,A Ramadan,D Bianchini,A Clarke,M Naji,G Ellul,P Brulinski

doi:10.1016/j.clon.2021.11.032

Use of Novel Imaging for Patient Selection for Stereotactic Ablative Radiotherapy (SABR) in Oligometastatic Prostate Cancer (PCa): Does the PET Tracer Make a Difference?

J.R Galante, S Adeleke + Show 14 more

https://doi.org/10.1016/j.clon.2021.11.032

Copy DOI

Journal: Clinical oncology (Royal College of Radiologists (Great Britain))

Publication Date: Feb 7, 2022

Affiliation: Maidstone and Tunbridge Wells NHS Trust, Kent and Canterbury Hospital, Dartford And Gravesham NHS Trust

#Oligometastatic Prostate Cancer #PSMA PET-CT + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Purpose: PSMA PET-CT has been shown to demonstrate superior diagnostic accuracy to choline PET-CT for metastatic disease [1,2] although clinical availability of these imaging techniques is heterogenous. We report on differences between these modalities, focusing on metastatic/recurrent disease detection rates and referrals for SABR in the context of oligometastatic disease.

Full Text